Applies to Employer and ACA Marketplace plans.
Covered (preferred drug)Qualification pathways
You can qualify through any one of these.
Initial approval for Type 2 Diabetes
All of:
- Diagnosis of Type 2 diabetes mellitus
- Patient is at least 18 years of age
- A1C ≥ 7% and ≤ 9%
- Trial and failure of, or intolerance to at least 2 oral antidiabetic agents used in combination OR insulin, at maximal daily doses for at least 3 continuous months, in conjunction with diet and exercise per ADA Standards of Care, with inadequate glycemic control — documented within the last 6 months
Documentation to bring
- Documentation of Type 2 diabetes mellitus diagnosis
- ICD-10 diagnosis code for type 2 diabetes (E11.0–E11.9) — required on file for Traditional formulary PA
- A1C lab result showing value ≥ 7% and ≤ 9% (within last 6 months)
- Documentation of trial and failure of at least 2 oral antidiabetic agents used in combination OR insulin at maximal daily doses for at least 3 continuous months, with inadequate glycemic control, within the last 6 months
- Documentation that treatment was in conjunction with diet and exercise per ADA Standards of Care
Not covered when
- Medications in this category are only covered for type 2 diabetes mellitus
- Type 1 diabetes
Policy note: Mounjaro is listed as a Preferred Agent alongside Trulicity (dulaglutide) under the GLP-1 Receptor Agonists class. The policy explicitly states these medications are only covered for type 2 diabetes mellitus under the Priority Health Optimized and Traditional Formularies. For the Traditional formulary, PA is triggered only if the T2DM ICD-10 code is not already on file; for the Optimized formulary, the full criteria above always apply. No continuation/renewal criteria, quantity limits, or approval duration is stated for GLP-1s in this document. The document does not address weight loss, CV risk reduction, OSA, MASH, or CKD indications for any GLP-1.
Policy effective December 1, 2024 · verified June 10, 2026 · source: 81 Dace8 F00 Ff442799502209 Cc51780 F